Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eisai Ltd ADR (OP: ESALY )

N/A UNCHANGED
Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eisai Ltd ADR

< Previous 1 2 3 4 5 6 7 Next >
Catalyst Pharma Acquires US Rights To Eisai's Epilepsy Drug
Via Benzinga
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
From Eisai
Via JCN Newswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
From Eisai
Via JCN Newswire
Why 2023 Could Be a Big Year for Biogen
Investors will soon learn if the company's Alzheimer's treatment gets the green light. 
Via The Motley Fool
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
From Eisai
Via JCN Newswire
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies
From Eisai
Via JCN Newswire
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting
From Eisai
Via JCN Newswire
Even After This Year’s Melt-Up, Runway Remains for LLY Stock
The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making. 
Via InvestorPlace
Can These 2 Stocks Crush the Market Again in 2023?
Both are riding the wave of major clinical wins 
Via The Motley Fool
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). 
Via Benzinga
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
Via Benzinga
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference
From Eisai
Via JCN Newswire
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine
From BiogenEisai
Via JCN Newswire
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies. 
Via Investor's Business Daily
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that... 
Via Benzinga
2 Stocks Near 52-Week Highs That Could Climb Higher
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research
From Eisai
Via JCN Newswire
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
Via Benzinga
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Via Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment. 
Via Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future. 
Via The Motley Fool
Is Biogen a Buy After It Boosted Guidance?
There's a much bigger story for this biotech than its improved 2022 outlook. 
Via The Motley Fool
Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug
Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month. 
Via Investor's Business Daily
Biogen Q3 Earnings Preview: Key Items For Investors To Watch
Biogen Inc (NASDAQ: BIIB) is scheduled to report its third-quarter earnings on Tuesday during the premarket session amid cautious hope for its neurodegenerative disease programs and an ongoing 
Via Benzinga
3 Alzheimer's Therapy Stocks to Invest in
Alzheimer's treatments could make a big winner of these stocks. 
Via The Motley Fool
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
Via Benzinga
Hey Biogen Investors, Don’t Chase BIIB Stock!
If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.